Navigation Links
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
Date:9/3/2008

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence anti-HAAH monoclonal antibody covered under this patent, as a cancer therapeutic antibody drug and anticipates the start of Phase 1 clinical trials in early 2009.

HAAH is a cancer molecular marker that has been detected by immunohistochemical staining in a broad range of cancers; this marker was originally discovered at the Rhode Island Hospital / Brown University. Research done both at Panacea and in collaboration with Brown University / Rhode Island Hospital has established HAAH as an excellent drug target for cancer therapy as well as a marker for cancer diagnosis. HAAH over-expression has been observed in more than twenty different cancers, and HAAH has been shown to be highly specific for cancer and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals. In cancer, HAAH is found on the cell surface and in normal cells found in minute quantities inside the cell. As such, HAAH is an excellent therapeutic target. Panacea has demonstrated the efficacy of PAN-622, an all-human sequence anti-HAAH monoclonal antibody, in animal models of cancer. In these experiments PAN-622 inhibited tumor growth in 90 percent of animals, with 40 percent showing no visible tumor. Tumors did not re-grow beyond the period of drug administration. Due to its all human sequence, PAN-622 is anticipated to have low toxicity in humans. And PAN-622 is currently being manufactured under cGMP at high yields.
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  PCI is pleased to announce it has ... leading provider of Clinical Trial Services and Temperature ... Wales in the United ... presence in the UK/EU to support global investigational ... and distribution capacity, as well as consultative services ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)... , September 18, 2014 ... http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition of ... Report"  report to their offering.  ... the worldwide markets for Sugar Alcohols in ... Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care Products, ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
(Date:9/19/2014)... 2014 Are you tired of having ... with seasonal allergies or sinus congestion? Fortunately, an inventor ... , She conceived of Nose Pal to avoid ... nose in public. Since it prevents nasal drip and ... conditions, particularly when cooking or working closely with others. ...
(Date:9/19/2014)... (HealthDay News) -- As kids transition from elementary to ... according to a recent study. But the ... found that verbal and physical bullying declines as students ... and prevention strategies must address all types of bullying ... girls, the researchers said. The study was published recently ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Your brain structure could help predict ... study suggests. Researchers at Yale University found those with ... the parietal cortex may be more likely to engage in ... , , The study, funded by the U.S. National Institute ... women living in the Northeast. The researchers sought to determine ...
Breaking Medicine News(10 mins):Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2
... Indiana University study found that young, female breast cancer ... and are interested in using sexual enhancement products to ... Cancer Survivors: Their sexual function and interest in sexual ... the journal Cancer Nursing . , The study ...
... reduced chances by 26% , , SUNDAY, Nov. 9 (HealthDay News) ... an extra benefit: a reduction in their risk of developing ... under the age of 52, according to research that was ... in New Orleans. , The findings, the first to demonstrate ...
... to protect healthy men, either , , SUNDAY, Nov. 9 ... doubt on the cardiac benefits of either low-dose aspirin ... low-dose aspirin did not reduce the risk of cardiovascular ... Harvard researchers concluded that neither vitamin E nor vitamin ...
... Low-dose aspirin as primary prevention did not appear to ... of coronary, cerebrovascular and peripheral vascular events in patients ... in JAMA . However, aspirin did significantly reduce ... The article is being released early online Sunday, November ...
... informed its readers of serious drug reactions and fatalities, which have ... as Heparin. The drug, from Baxter Healthcare, was found to be ... ... Denver (PRWEB) November 9, 2008 -- LegalView.com, the number one legal ...
... they have risk factors that could lead to coronary ... -- Despite certain risk factors, Hispanic patients were 57 ... bypass surgery (CABG) one year after successful angioplasty to ... It also found that Hispanics were less likely to ...
Cached Medicine News:Health News:Sexual intimacy and breast cancer survivors: New research 2Health News:Flu Shots Lower Risk of Blood Clots 2Health News:Flu Shots Lower Risk of Blood Clots 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 2Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 3Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 4Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 2Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 3Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 4Health News:Hispanics Less Likely to Get Repeat Artery Surgery 2
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: